Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
- DOI
- 10.1007/s40264-019-00886-3
- Published
- 2020-03-01
- Container
- Drug Saf
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40264-019-00886-3,
title = {Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.},
author = {Kolberg HC and Colleoni M and Demetriou GS and Santi P and Tesch H and Fujiwara Y and Tomasevic Z and Hanes V.},
year = {2020},
journal = {Drug Saf},
doi = {10.1007/s40264-019-00886-3},
url = {https://doi.org/10.1007/s40264-019-00886-3}
}RIS
TY - JOUR TI - Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. AU - Kolberg HC AU - Colleoni M AU - Demetriou GS AU - Santi P AU - Tesch H AU - Fujiwara Y AU - Tomasevic Z AU - Hanes V. PY - 2020 JO - Drug Saf DO - 10.1007/s40264-019-00886-3 UR - https://doi.org/10.1007/s40264-019-00886-3 ER -
APA
HC, K., M, C., GS, D., P, S., H, T., Y, F., Z, T., & V., H. (2020). Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.. Drug Saf. https://doi.org/10.1007/s40264-019-00886-3
Source records
- europe-pmc · retrieved 2026-09-27T13:07:00.128Z